The North America Autoimmune Disease Diagnosis Market is witnessing robust growth, driven by technological innovations and increased prevalence of autoimmune disorders. The market was valued at USD 5,320 Million in 2025 and is projected to reach USD 12,456 Million by 2035, expanding at a CAGR of 7.9% from 2024 to 2035.
The economic impact of tariffs on "North America Autoimmune Disease Diagnosis Market".
Market Growth Drivers
Rising Prevalence of Autoimmune Diseases: The incidence of autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis has been increasing steadily across North America. This has led to heightened demand for early and accurate diagnostic solutions. Companies like Abbott Laboratories have introduced advanced ELISA and immunoassay kits, enabling healthcare professionals to rapidly diagnose and monitor autoimmune conditions. The rising burden of these diseases is compelling diagnostic companies to invest in innovation and expand their test portfolios, fostering market growth.
Technological Advancements and Automation: The integration of advanced technologies such as next-generation sequencing (NGS), multiplex assays, and automated diagnostic platforms is transforming the autoimmune disease diagnosis market. Thermo Fisher Scientific, for instance, has launched automation-enabled platforms that increase test throughput while reducing human error, driving adoption in hospitals and reference labs. These technologies facilitate faster, more reliable diagnosis, enabling tailored treatment regimens and improved patient outcomes, and significantly contributing to market expansion.
Market Trends
Shift Towards Personalized Medicine: The autoimmune disease diagnosis landscape in North America is experiencing a major shift towards personalized and precision medicine. Technologies like molecular diagnostics and biomarker-based testing are enabling identification of disease subtypes and patient-specific risk factors. For example, Quest Diagnostics is leveraging genomic profiling for more targeted diagnosis and treatment recommendations. This trend is resulting in improved management protocols and patient satisfaction.
Integration of Artificial Intelligence (AI) in Diagnostic Procedures: AI-driven analytics and machine learning algorithms are being adopted to enhance diagnostic accuracy, predict disease progression, and streamline workflow. Companies such as Bio-Rad Laboratories have begun integrating AI solutions with existing diagnostic platforms to interpret complex patterns in autoimmune disease biomarkers. This reduces diagnostic time, enhances reliability, and supports clinical decision-making, demonstrating a transformative impact on diagnostic processes.
Market Opportunities
Expansion into Point-of-Care Diagnostics: The growing demand for rapid, accessible testing is giving rise to significant opportunities in point-of-care autoimmune disease diagnostics. Companies like Siemens Healthineers are focusing on the development of handheld and portable diagnostic devices to enable near-patient testing and expand reach in remote areas.
Collaboration with Research Institutions: Strategic partnerships between diagnostic companies and academic research centers enable the development of novel biomarkers and advanced diagnostic tools. This collaboration accelerates innovation and expands market opportunities for early detection solutions.
North America Autoimmune Disease Diagnosis Market Revenue (USD Million), 2020-2035
The market revenue chart illustrates steady and sustained growth from 2020 to 2035. Starting at USD 3,150 Million in 2020, the market value has experienced incremental annual growth, primarily propelled by increasing diagnosis rates, technological innovations, and healthcare infrastructure improvements. The forecast projects the market reaching USD 5,320 Million by 2025 and accelerating to USD 12,456 Million by 2035, reflecting the region’s focus on research, adoption of automated diagnostic solutions, and a rise in autoimmune disease cases. This upward trend underscores the critical role diagnostics play in disease management and the growing investment in healthcare technology.
North America Autoimmune Disease Diagnosis Market by Region Share (%), 2025
The 2025 regional market share distribution shows the United States leading with 72% of the total market, given its advanced healthcare infrastructure and higher diagnosis rates. Canada holds 18%, driven by rising awareness and government initiatives. Mexico captures 6% due to growing healthcare investments. The remaining 4% is shared among other regions, including US territories such as Puerto Rico and Bermuda. This pie chart visually reflects the market's concentration and the potential growth areas within North America, emphasizing the significant role of the US in advancing autoimmune disease diagnostics.
Recent Developments
In May 2024, Abbott Laboratories expanded its FDA-approved autoimmune panel to include new biomarkers for early-stage lupus diagnosis. This innovation facilitates earlier and more precise identification, ultimately improving patient care pathways and outcomes.
In April 2024, Thermo Fisher Scientific announced a collaboration with the University of Toronto for the development of multiplexed assay platforms targeting rare autoimmune disease diagnostics, aiming to accelerate research and improve test accuracy.
In March 2024, Quest Diagnostics launched an AI-powered diagnostic platform that integrates electronic health record (EHR) data for comprehensive autoimmune disease screening. This launch is expected to enhance diagnostic efficiency in major North American hospitals and clinics.
Press Releases